NCT01427205View on ClinicalTrials.gov

Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2013

Primary Completion Date

June 30, 2016

Conditions
Head and Neck Cancer
Interventions
DRUG

Cetuximab

Loading dose 400 mg/m2 by vein once followed by 250 mg/m2 weekly (+/- 7 days).

DRUG

OSI-906

150 mg by mouth twice a day.

OTHER

Placebo

Placebo taken by mouth twice daily.

Sponsors

Collaborators (1)

OSI Pharmaceuticals
All Listed Sponsors
collaborator

OSI Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER